Canopy acquires Czech Annabis Medical sro Canopy Growth Corp. is growing its medical cannabis business in Europe with the acquisition of Czech market leader Annabis Medical sro. more ➔
New Pierre Guerin site in Hildesheim, GermanyMid last year, the company Pierre Guerin has opened a new location in Germany, Hildesheim. more ➔
GSK pass orphan gene therapy assets to Orchard TherapeuticsBritish drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. … more ➔
Alexion in €639m bid for Wilson Therapeutics ABA public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics’ Board of Directors. Alexion’s SEK232/share bid would total in an acqusition price … more ➔
Novartis enters SMA race acquiring AveXis for US$8.7bn Swiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis … more ➔
Blood test predincting Alzheimer’s paves way to earlier therapyA newly developed blood test indicates Alzheimer’s disease on average eight years before the clinical diagnosis. more ➔
Poor investigator brochures: Resarchers call for standardisationHuman drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by … more ➔
Ose and Boehringer ink €1.1bn deal in immunoncologyFrench Ose Immunotherapeutics SA has licenced global commercialisation rights of its preclinical programme OSE-172 to Boehringer Ingelheim which hopes to complement its immunoncology portfolio … more ➔
Cellectis in offering of US$175m ADS following asset swapFrench allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of Cellectis. more ➔
Motif Bio to submit NDA for iclaprim Motif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) … more ➔
